Indication

For treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.

Medicine details

Medicine name:
enzalutamide (Xtandi)
SMC ID:
SMC2400
Pharmaceutical company
Astellas Pharma Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
14 February 2022
SMC meeting date:
11 January 2022
Patient group submission deadline:
01 November 2021